Back to Browse Journals » Vascular Health and Risk Management » Volume 3 » Issue 6

A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications

Authors Behzad Molavi, Negah Rassouli, Suveer Bagwe, Neda Rasouli

Published Date January 2007 Volume 2007:3(6) Pages 967—973

DOI

Published 15 January 2007

Behzad Molavi1, Negah Rassouli2, Suveer Bagwe1, Neda Rasouli2

Central Arkansas Veterans Healthcare System and University of Arkansas for Medical sciences, 1Division of cardiology and 2Division of Endocrinology, College of Medicine, Little Rock, Arkansas, USA

Abstract: The rising incidence of obesity and insulin resistance to epidemic proportions has closely paralleled the surge in the prevalence of diabetes and outpaced therapeutic advances in diabetes prevention and treatment. Current evidence points to obesity induced oxidative stress and chronic inflammation as the common denominators in the evolution of insulin resistance and diabetes. Of all the hypoglycemic agents in the pharmacological arsenal against diabetes, thiazolidinediones, in particular pioglitazone, as well as metformin appear to have additional effects in ameliorating oxidative stress and inflammation; rendering them attractive tools for prevention of insulin resistance and diabetes. In addition to their hypoglycemic and lipid modifying properties, pioglitazone and metformin have been shown to exert anti-oxidative and anti-inflammatory effects in vascular beds, potentially slowing the accelerated atherosclerosis in diabetes, which is the major cause of morbidity and mortality in the affected population. The combination of pioglitazone and metformin would thus appear to be an effective pharmacological intervention in prevention and treatment of diabetes. Finally, this review will address the currently available evidence on diabetic cardiomyopathy and the potential role of combination therapy with pioglitazone and metformin.

Keywords: insulin resistance, oxidative stress, inflammation, pioglitazone, metformin, atherosclerosis, diabetic cardiomyopathy

Download Article [PDF] 

Readers of this article also read:

Glimepiride: evidence-based facts, trends, and observations

Basit A, Riaz M, Fawwad A

Vascular Health and Risk Management 2012, 8:463-472

Published Date: 15 August 2012

Frontalis sling procedure for ocular myasthenia gravis

Asamura S, Kakizaki H, Enjyo M, Hashimoto T, Isogai N

Clinical Ophthalmology 2012, 6:575-577

Published Date: 12 April 2012

Optic nerve sheath fenestration in cryptococcal meningitis

Tatyana Milman, Neena Mirani, Roger E Turbin

Clinical Ophthalmology 2008, 2:637-639

Published Date: 6 October 2008

Analysis of sFas IL-6 levels in thyroid-associated ophthalmopathy: Pre- or poststeroid pulse treatment

Kimihito Maeda, Yuichiro Ohara, Masato Hashimoto, Hiroshi Ohguro

Clinical Ophthalmology 2008, 2:609-612

Published Date: 5 October 2008

Early vascular aging (EVA): consequences and prevention

Peter M Nilsson

Vascular Health and Risk Management 2008, 4:547-552

Published Date: 30 June 2008

Arterial Stiffness and Pharmacological Interventions – The TRanscend Arterial stiffNess Substudy (TRANS study)

Jirar Topouchian, Ramzi El Feghali, Bruno Pannier, Shuyu Wang, Feng Zhao, Karel Smetana, Koon Teo, Roland Asmar

Vascular Health and Risk Management 2007, 3:381-388

Published Date: 4 October 2007

A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice

Maddalena Veronesi, Arrigo FG Cicero, Maria Grazia Prandin, Ada Dormi, Eugenio Cosentino, et al

Vascular Health and Risk Management 2007, 3:999-1005

Published Date: 15 January 2007

Choroidal neovascular membrane following clear lens extraction

Banu Turgut Öztürk, Hürkan Kerimoglu, Ümit Kamis, Saban Gönül, Süleyman Okudan

Clinical Ophthalmology 2007, 1:559-561

Published Date: 11 January 2007